Shares Outstanding Shares Outstanding n/a Close	12.97M
Shares Change (YoY) Shares Change (YoY) n/a Close	140.12%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	55.44%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	99.99%
Shares Floating Shares Floating n/a Close	7.67M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	7,262
FTD / Avg. Volume FTD / Avg. Volume n/a Close	1.88%

Short Selling Information

The latest short interest is 474.26K, so 3.66% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	474.26K
Short % of Shares Out Short % of Shares Out n/a Close	3.66%
Short % of Float Short % of Float n/a Close	3.66%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	2.27

Valuation Ratios

The PE ratio is -1.01 and the forward PE ratio is -6.44. Cidara Therapeutics's PEG ratio is 0.

PE Ratio PE Ratio n/a Close	-1.01
Forward PE Forward PE n/a Close	-6.44
PS Ratio PS Ratio n/a Close	133.87
Forward PS Forward PS n/a Close	3.4
PB Ratio PB Ratio n/a Close	1.05
P/FCF Ratio P/FCF Ratio n/a Close	-0.97
PEG Ratio PEG Ratio n/a Close	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cidara Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.02.

Current Ratio Current Ratio n/a Close	4.25
Quick Ratio Quick Ratio n/a Close	4.25
Debt / Equity Debt / Equity n/a Close	0.02
Debt / EBITDA Debt / EBITDA n/a Close	-0.02
Debt / FCF Debt / FCF n/a Close	-0.02
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$33,552.63
Profits Per Employee Profits Per Employee n/a Close	$-4,469,131.58
Employee Count Employee Count n/a Close	38
Asset Turnover Asset Turnover n/a Close	0.01
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by 329.31% in the last 52 weeks. The beta is 0.8, so Cidara Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.8
52-Week Price Change 52-Week Price Change n/a Close	329.31%
50-Day Moving Average 50-Day Moving Average n/a Close	24.3
200-Day Moving Average 200-Day Moving Average n/a Close	19.73
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	81.64
Average Volume (20 Days) Average Volume (20 Days) n/a Close	386,648

Income Statement

In the last 12 months, Cidara Therapeutics had revenue of 1.27M and earned -169.83M in profits. Earnings per share was -26.75.

Revenue Revenue n/a Close	1.27M
Gross Profit Gross Profit n/a Close	1.04M
Operating Income Operating Income n/a Close	-176.1M
Net Income Net Income n/a Close	-169.83M
EBITDA EBITDA n/a Close	-176.1M
EBIT EBIT n/a Close	-176.1M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-26.75

Full Income Statement

Balance Sheet

The company has 189.82M in cash and 3.58M in debt, giving a net cash position of 186.25M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	189.82M
Total Debt Total Debt n/a Close	3.58M
Net Cash Net Cash n/a Close	186.25M
Retained Earnings Retained Earnings n/a Close	-611.26M
Total Assets Total Assets n/a Close	191.73M
Working Capital Working Capital n/a Close	140.04M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -176.53M and capital expenditures -129K, giving a free cash flow of -176.66M.

Operating Cash Flow Operating Cash Flow n/a Close	-176.53M
Capital Expenditures Capital Expenditures n/a Close	-129K
Free Cash Flow Free Cash Flow n/a Close	-176.66M
FCF Per Share FCF Per Share n/a Close	-27.82

Full Cash Flow Statement

Margins

Gross margin is 81.73%, with operating and profit margins of -13811.92% and -13319.76%.

Gross Margin Gross Margin n/a Close	81.73%
Operating Margin Operating Margin n/a Close	-13811.92%
Pretax Margin Pretax Margin n/a Close	-13356.16%
Profit Margin Profit Margin n/a Close	-13319.76%
EBITDA Margin EBITDA Margin n/a Close	-13811.92%
EBIT Margin EBIT Margin n/a Close	-13811.92%
FCF Margin FCF Margin n/a Close	-13855.84%

Dividends & Yields

CDTX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for CDTX is $47, which is -2.2% lower than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$47
Price Target Difference Price Target Difference n/a Close	-2.2%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	8

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Apr 24, 2024. It was a backward split with a ratio of 1:20.

Last Split Date Last Split Date n/a Close	Apr 24, 2024
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:20

Scores

Altman Z-Score Altman Z-Score n/a Close	-2.09
Piotroski F-Score Piotroski F-Score n/a Close	1